West, R. Enhancing Motivation to Stop Smoking: From Theory to Practice. Cancer Research UK. UK Centre for Tobacco Control Studies: A UKCRC Public Health Centre of Excellence. August, 2014.
Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco Use in Canada: Patterns and Trends, 2014 Edition. Waterloo, ON: Propel Centre for Population Health Impact, University of Waterloo.
Davis RM. Uniting Physicians Against Smoking: The Need For A Coordinated National Strategy. JAMA 1988; 259:2900–2901.
Fiore MC, Jaén CR, Baker TB, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. Am J Prev Med 2000;35(2):158-176.
Cummings KM and Hyland A. Impact of Nicotine Replacement Therapy on Smoking Behaviour. Anny Rev Public Health 2005;26:583-599.
Fiore MC, Jaén CR, Baker TB, et al. Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update.
Fowler G. Helping Smokers to Stop: An Evidence-Based Approach. Practitioner 2000 Jan;244(1606):37-41.
Slama, KJ, Redman, S, Cockburn J, et al. Community View about the Role of General Practitioners in Disease Prevention Family Practice 1989;6(3):203-209.
Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco Use in Canada: Patterns and Trends, 2015 Edition. Waterloo, ON: Propel Centre for Population Health Impact, University of Waterloo.
Stead LF, Bergson G, and Lancaster T. Physician Advice for Smoking Cessation (Review).Cochrane Database of Systematic Reviews 2008; Issue 2.
Centers for Disease Control and Prevention. Using Proven Treatments Can Double Your Chance of Success. May 11, 2015.
Bondy SJ, Diemer LM, Victor JC, et al. Assessing the Reach of Nicotine Replacement Therapy as a Preventive Public Health Measure. Chronic Dis Injur Can 2012;33(1):19-28.
NICORETTE® Gum Product License. August 11, 2011.
Lindson-Hawley N, Aveyard P and Hughes JR. Reduction Versus Abrupt Cessation in Smokers Who Want to Quit. Cochrane Database of Systematic Reviews 2012; Issue 11.
Shiffman S, Hughes JR, Ferguson SG, et al. Smokers’ Interest in Using Nicotine Replacement to Aid Smoking Reduction. Nicotine Tob Res 2007;9(11): 1177-1182.
Rapuach T, Brown J, Herbec A, et al. A Systematic Review of Studies Assessing the Association Between Adherence to Smoking Cessation Medication and Treatment Success. Addiction 2013;109:35-43.
Tonnesen P, Paoletti P, Gustavsson G, et al. Higher Dosage Nicotine Patches Increase One-Year Smoking Cessation Rates; Results from the European CEASE Trial. Eur Respir J 1999;13:238-246.
Burns WK and Levinson AH. Discontinuation of Nicotine Replacement Therapy among Smoking-Cessation Attempters. Am J Prev Med 2008;34(3):212-215.
Siahpush M, Shaikh R, McCarthy M, et al. Association Between Duration of Use of Pharmacotherapy and Smoking Cessation from a National Survey. BMJ 2015;5:e006229.
Ferguson S, Mitchell JG, Shiffman S, et al. Providing Accurate Safety Information May Increase a Smoker’s Willingness to Use Nicotine Replacement Therapy as Part of a Quit Attempt. Addictive Behav 2011;36:713-716.
Champix® Product Monograph. Pfizer Canada Inc. November 18, 2014.
Catz SL, Jack LM, McClure JB, et al. Adherence to Varenicline in the COMPASS Smoking Cessation Intervention Trial. Nicotine Tobacco Res 2011;13(5):361-388.
Hays JT, Leischow SJ, Lawrence D, et al. Adherence to Treatment for Tobacco Dependence: Association with Smoking Abstinence and Predictors of Adherence. Nicotine Tobacco Res 2010;12(6):574-581.
Fucito LM, Toll BA, Salovey P, et al. Beliefs and Attitudes About Bupropion: Implications for Medication Adherence and Smoking Cessation Treatment. Psychol Addictive Behav 2009;23(2):373-379.
World Heath Organization: Tobacco Smoking. 2003.
O’Donohue WT and Levensky ER. Promoting Treatment Adherence: A Practical Handbook for Health Care Providers. 2006; Sage Publications, Inc.
Garvey AJ, Bliss RT, Hitchcock JL, et al. Predictors of Smoking Relapse Among Self-Quitters: A Report from the Normative Aging Study. Addictive Behav 1992;17:367-377.
Rigotti NA. Strategies to Help a Smoker who is Struggling to Quit. JAMA 2012;308(15):1573-1580.
Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking Cessation Among Self-Quitters. Health Psychol 1992;11(5):331-334.
Aveyard P and Raw M. Improving Smoking Cessation Approaches at the Individual Level. Tobacco Control 2012;21:252-257.
Prochaska JO and DiClemente CC. Stages and Processes of Self-Change of Smoking: Toward an Integrative Model of Change. J Consult Clin Psychol 1983;51(3):390-395.
Russell MAH, Wilson C, Taylor C, et al. Effect of General Practitioners’ Advice Against Smoking BMJ 1979;2(6184):231-235.
Ockene JK and Zapka JG. Physician-Based Smoking Intervention: A Rededication to a Five-Step Strategy to Smoking Research Addictive Behav 1997;22(6):835-848.
Shiffman S, Ferguson SG, Rohay J, et al. Perceived Safety and Efficacy of Nicotine Replacement Therapies Among US Smokers and Ex-Smokers: Relationship with Use and Compliance. Addiction 2008;103:1371-1378.
NICODERM® Product License. February 16, 2016.
Houtsmuller EJ, Fant RV, Eissenberg TE, et al. Flavor Improvement Does Not Increase Abuse Liability of Nicotine Chewing Gum. Pharmacol Biochem Behav 2002;72:559-568.
Kipnis S, Killar R, Bonneau P. Tobacco Myths and Myth – Understandings. New York State Office of Health, Wellness and Medical Direction. October, 2007.
Cigarette Prices in Canada. Smoking and Health Action Foundation, Ottawa,(613) 230-4211. Available at: www.nsra-adnf.ca.
Nielsen Market Research Data.
McDonald J, Coady K and Saltman D. The Postal Code Lottery Of Cancer Prevention In Canada Discrepancies in Public and Private Funding for Smoking Cessation Products. Report Card on Cancer in Canada, 2012-2013.
Grana RA, Long PM, Benowitz N, et al. Electronic Cigarettes. Circulation 2014;129:e490-e492.
Nitzkin JL. The Case in Favor of E-Cigarettes for Tobacco Harm Reduction. Int J Environ Res Public Health 2014;11:6459-6471.
Polosa R, Rodu B, Caponnetto P, et al. A Fresh Look At Tobacco Harm Reduction: The Case For The Electronic Cigarette. Harm Red Journ 2013;10:1-11.
Farsalinos KE and Polosa R. Safety Evaluation And Risk Assessment Of Electronic Cigarettes As Tobacco Cigarette Substitutes: A Systematic Review. Ther Adv Drug Saf 2014;5(2):67-86.
NICORETTE® Inhaler Product License. December 14, 2007.
Bullen C, Howe C, Laugesen M, et al. Electronic Cigarettes for Smoking Cessation: A Randomised Controlled Trial. Lancet 2013;382:1629-1637.
Gennimmata SA. Acute Effect Of E-Cigarette On Pulmonary Function In Healthy Subjects And Smokers. European Respiratory Society Annual Congress 2012, Abstract 7098.
Vaikali S. Acute Impact Of A Single E-Cigarette Smoking On Symptoms, Vital Signs And Airway Inflammatory Response. European Respiratory Society Annual Congress 2012, Abstract 7207.
Vardavas CI, Anagnostopoulos N, Jougias M, et al. Short-Term Pulmonary Effects of Using an Electronic Cigarette. Chest 2012;141(6):1400-1406.
Jensen RP, Luo W, Pankow JF, et al. Hidden Formaldehyde in E-Cigarette Aerosols. NEJM 2015;372(4):393-294.
Sussan R, Gajghate S, Thimmulappa RK, et al. Exposure to Electronic Cigarettes Impairs Pulmonary Anti-Bacterial and Anti-Viral Defenses in a Mouse Model. PLOS One 2015; DOI:10.1371/journal.pone.0116861.
Oh AY and Kacker A. Do Electronic Cigarettes Impart a Lower Potential Disease Burden Than Conventional Tobacco Cigarettes?: Review on E-Cigarette Vapor Versus Tobacco Smoke. Laryngoscope 2014; 124:2702-2706.
Bertholon JF, Becquemin MH, Annesi-Maesano I. Electronic Cigarettes: A Short Review. Respiration 2013;86:433-438.
Hadwiger ME, Trehy ML, Ye W, et al. Identification Of Amino-Tadalafil And Rimonabant In Electronic Cigarette Products Using High Pressure Liquid Chromatography With Diode Array And Tandem Mass Spectrometric Detection. J Chromatogr 2010;1217:7547-7555.
McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic Cigarettes for Smoking Cessation and Reduction (Review). Cochrane Database of Systematic Reviews 2014(12):1-58.
Bullen C. Electronic Cigarettes for Smoking Cessation, Curr Cardiol Rep 2014;16:538.
Alberta Health Services. Tobacco Free Futures Guidelines. 2012. Available at: www.tobaccofreefutures.ca.
Canadian Association of Occupational Therapists Position Statement. The Role of Health Professionals in Tobacco Cessation (Joint Statement, June 2001). Available at: http://www.caot.ca/default.asp?pageid=245. Accessed May 13, 2015.
CAN-ADAPTT. Algorithm for Tailoring Pharmacotherapy in Primary Care Setting. March 2012-ed. Nov 2013.
McDermott MS, Marteau TM, Hollands GJ, et al. Change in Anxiety Following Successful and Unsuccessfully Attempts at Smoking Cessation: Cohort Study. Br J Psych 2013;202:62-67.
NICORETTE® QUICKMIST® Product License. January 18, 2013.
NICORETTE® Lozenge Product License. August 4, 2011.
Fagerstrom K and Hughes J. Varenicline In The Treatment Of Tobacco Dependence. Neuropsych Dis Treat 2008;4(2):353-363.
Koegelenberg CFN, Noor F, Bateman ED, et al. Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. JAMA 2014;312(2):155-161.
Tonstad S, Davies S, Flammer M. Psychiatric Adverse Events In Randomized, Double-Blind, Placebo-Controlled Clinical Trials Of Varenicline: A Pooled Analysis. Drug Saf 2011;33(4):289-301.
Spiegler P. Dual Therapy for Smoking Cessation. Clin Pulm Med 2014;21:288.
Warner C and Shoaib M. How Does Bupropion Work as a Smoking Cessation Aid? Addiction Biol 2005;10:219-231.
ZYBAN® Product Monograph. Valeant Canada LP. August 1, 2013.
Silagy C, Lancaster T, Stead L, et al. Nicotine Replacement Therapy for Smoking Cessation (Review). Cochrane Database of Systematic Reviews 2004; Issue 3.
CAN-ADAPTT .(2011). Canadian Smoking Cessation Clinical Practice Guideline. Toronto, Canada: Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment, Centre for Addiction and Mental Health.
Asfar T, et al. Do Smoking Reduction Interventions Promote Cessation in Smokers Not Ready to Quit? Addict Behav2011;36:764-768.
Ellerbeck EF, et al. Effect of Varying Levels of Disease Management on Smoking Cessation. Ann Intern Med 2009;150:437-446.
Pisinger C, et al. Is it Possible to Help Smokers in Early Motivational Stages to Quit. The Inter99 Study. Prev Med 2005;40:278-284.
Richter KP. Do we Really Need to Assess Tobacco Users’ Willingness to Quit? Presentation to the University of Kansas School of Medicine.
Hughes JR, et al. Intentions to Quit Smoking Change Over Short Periods of Time. Addict Behav2005;30:653-662.
Richter KP, et al. It’s Time to Change the Default for Tobacco Treatment. Addiction 2014;110:381-386.
Aveyard P, et al. Brief Opportunistic Smoking Cessation Interventions: A Systematic Review and Meta-Analysis to CompareAdvice to Quit and Offer of Assistance. Addiction 2011;107:1066-1073.
Conroy MB, et al. The Association Between Patient-Reported Receipt of Tobacco Intervention at a Primary Care Visit and Smokers' Satisfaction with their Health Care.Nicotine TO Res 2005;7(Suppl 1):S29-S34.
Hughes JR. An Updated Algorithm for Choosing Among Smoking Cessation Treatments.J Subst Abuse Treat 2013;45: 215-221.
Reid RD, Pritchard G, Walker K, et al. Managing Smoking Cessation. CMAJ 2016;188(17-18): E484-E492. Epub 2016 Oct 3.
Diefenbach L, et al. What is the Most Effective Nicotine Replacement Therapy? J Fam Pract 2003;52(6):492-494.
Burris JL et al. A Mechanistic Test of Nicotine Replacement Therapy Sampling for Smoking Cessation Induction. Psychol Addict Behav 2015 Jun;29(2):392-399.
Shiffman S. Nicotine Replacement Therapy Increases Quit Attempts Among Unmotivated Smokers When Added to Encouragement to Practice Quitting. Evidence-Based Medicine 2012;17(6):187-188.
Hughes JR, et al. Shape of the Relapse Curve and Long-term Abstinence Among Untreated Smokers. Addiction 2004l99:29-38.
Knight C, et al. The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO Model. Value in Health 2010;13(2):209-214.
Anthenelli RM, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387(10037):2507-2520.
Chang P-H, et al. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Pub Health 2015;15:689.
Kaplan A. Can electronic cigarettes assist patients with smoking cessation?:Yes Can Fam Physician 2015;61:499-500.
Garcia-Arcos I, et al. Chronic Electronic Cigarette Exposure in Mice Induces Features of COPD in a Nicotine-Dependent Manner. Thorax 2016;71:1119–1129. doi:10.1136/thoraxjnl-2015-208039.
Sherwood C and Boitano B. Airway Epithelial Cell Exposure to Dstinct E-cigarette Liquid Flavorings Reveals Toxicity Thresholds and Activation of CFTR by the Chocolate Flavoring 2,5-Dimethypyrazine Features of COPD in a Nicotine-Dependent Manner. Respiratory Research 2016;17:57 DOI 10.1186/s12931-016-0369-9.
Siegel MB, Tanwar KL, Wood KS. Electronic Cigarettes as a Smoking-Cessation Tool: Results From an Online Survey. Am J Prev Med 2011;40:472-475.
Beiner L and Hargraves JL. A Longitudinal Study of Electronic Cigarette Use in a Population-Based Sample of Adult Smokers: Association With Smoking Cessation and Motivation to Quit. Nicotine Tob Res 2014;doi: 10.1093/ntr/ntu200.
Malas M, van der Tempel J, Schwartz R, et al. Electronic cigarettes for smoking cessation: A systematic review. Nicotine Tob Res 2016;18(10):1926-1936.
Fairchild A, Bayer R, Colgrove J. The Renormalization of Smoking? E-Cigarettes and the Tobacco “Endgame” N Engl J Med 2014; 370:293-295January 23, 2014DOI: 10.1056/NEJMp1313940.
Czoli C, Hammond D, White C. Electronic cigarettes in Canada: Prevalence of use and perceptions among youth and young adults. Can J Public Health 2014;105(2):e97-e102.
Schripp T, Markewitz D, Uhde E, et al. Does e-cigarette consumption cause passive vaping? Indoor Air. 2013;23:25–31.